Introduction
============

Osteopetrosis is a group of genetic disorders characterized by increased bone mass and density due to defective bone resorption [@B1]. Currently, the candidate genes of osteopetrosis include *IKBKG, CLCN7*, *OSTM1*, *TCIRG1*, *PLEKHM1*, *CAII*, *RANK*, and *RANKL* [@B1],[@B2]*.* Human *CLCN7* encoding voltage-gated chloride channel 7 (ClC-7) is one of the key molecules involved in osteopetrosis [@B2]-[@B5]. In our previous study, we reported two osteopetrosis patients with *CLCN7* mutations, who had impacted teeth, enamel dysplasia, malformed teeth, altered tooth eruption and root dysplasia [@B6]-[@B8]. A few years later, our group and other groups showed that *Clcn7* deficiency displayed dental defects in tooth eruption or root formation [@B7],[@B9]-[@B11]. All of these findings provided new insights to further understand the pathological mechanisms of *CLCN7*-related osteopetrosis.

According to our previous clinical observations and some other references [@B12], craniofacial bone dysplasia is quite common in osteopetrosis patients. It is unclear whether these phenotypes are the typical features of *CLCN7* involved osteopetrosis and whether or how these phenotypes were caused by ClC-7 deficiency.

Some signaling molecules, including BMP, TGF-β1, FGF, Hedgehog, and Wnt, are involved in the regulation of craniofacial pattern [@B13]-[@B17]. The balance between BMP2 and TGF-β1 signaling pathway could be affected by cathepsin K (CTSK), which is one of the important factors for osteoclastic function and development [@B18]. Several studies reported that ClC-7 deficiencies in humans and mice disrupted osteoclastic function and bone resorption [@B19]-[@B22], and resulted in decreased lysosome luminal Cl^-^ concentration [@B23],[@B24]. Hence, in this study, we wondered if ClC-7 could influence CTSK by changing the local luminal condition, which affects the downstream balance between BMP2 and TGF-β1. This remains to be a key mechanism by which ClC-7 affects craniofacial bone and tooth development.

Methods
=======

Literature review of craniofacial and dental phenotypes in osteopetrosis
------------------------------------------------------------------------

Related osteopetrosis references were searched to summarize the general craniofacial and dental phenotypes in osteopetrosis patients. The following keywords were used to search the references (1965 to present) from PubMed: osteopetrosis, osteomyelitis, mandible, maxilla, tooth, craniofacial, skull, and calvarium. The 58 papers in PubMed matched the searching criteria and only those references showing detailed clinical craniofacial and dental phenotypes were included in our analysis. Finally, 80 osteopetrosis cases from 41 references were included to summarize the general characteristics of abnormal craniofacial and dental phenotypes. The genetic background for most of the cases was not mentioned (Supplementary references).

Pedigree analysis and DNA sequencing
------------------------------------

Five osteopetrosis patients with *CLCN7* mutations from four families were recruited in the Clinic of Oral Rare Diseases and Genetic Diseases, School of Stomatology at the Fourth Military Medical University (Xi\'an, China). The patients were clinically examined and detected using different X-ray techniques including panoramic radiograph, CT, or RVG dental film as previously described [@B6]. The patients diagnosed with osteopetrosis demonstrated increased bone mass and frequent fractures. This study was approved by the Ethics Committee of the School of Stomatology, Fourth Military Medical University (Approval No. 2012-2-8). Informed consent was obtained from the patients and their family members. Total genomic DNA of patients and their family members was obtained from whole blood [@B25]. The *CLCN7* gene was amplified using polymerase chain reaction (PCR) for sequencing as described previously [@B26]. Sequence maps were analyzed using Sequencher software (version 5.0, Gene Codes Corporation, Ann Arbor, MI, USA). The new finding variants were identified in at least fifty healthy controls.

Zebrafish husbandry
-------------------

Embryos and adult AB strain zebrafish were raised and maintained [@B27]. Embryos were incubated with 0.004% 1-phenyl 2-thiourea (PTU) to avoid pigmentation. Euthanasia and handling of zebrafish in the experiments were performed according to the policies of Institutional Animal Care of the School of Stomatology, the Fourth Military Medical University.

Morpholino injection and rescue experiments
-------------------------------------------

The standard control morpholino oligonucleotide (MO) (5\' - CCTCTTACCTCAGTTACAATTTATA-3\') and a translation blocking MO (tbMO) by the sequence (5\'-CCTGCTAAGCAGAGAACTACTGCGT-3\') targeting -31 to -55 in exon 1 of zebrafish *clcn7* were obtained from Gene Tools, LLC (Philomath, OR). A 1 nL of 0.25 nM *clcn7* MO was injected into the embryos of zebrafish at one-cell stage using a gas-driven microinjector. The efficiency of MO was evaluated by measuring the expression of *clcn7* as assessed by Q-PCR and phenotypic penetrance. The injected embryos were cultured in the embryo medium and harvested at 3 dpf (days post-fertilization) or 5 dpf for the following experiments [@B28].

Full-length human *CLCN7* cDNA was amplified and subcloned into vector pCS2-EGFP. Sequencing confirmed that all the amplified sequences synthesized a complete open reading frame with EGFP sequence. The constructed vectors were digested using Not I, and the mRNAs were synthesized *in vitro* using mMESSAGE Sp6 transcription kit (Ambion, Austin, Texas, USA). MO and mRNA were co-injected into zebrafish embryos of one-cell stage. Emission fluorescence of EGFP and phenotype was observed under a fluorescence microscope (Leica M165 FC, Heidelberger, Germany).

Qualitative transcript analysis
-------------------------------

Total RNA was extracted from pooled 0.75 hpf (hours post-fertilization), 4 hpf, 6 hpf, 12 hpf, 1 dpf, 2 dpf, 3 dpf and 4 dpf larvae (n = 50) using Trizol reagent (Life Technologies, Carlsbad, USA). The qualities of the isolated RNA were tested as described previously [@B29]. cDNA was reverse-transcribed using PrimeScript^TM^ RT Master Mix according to the manufacturer\'s protocol (TaKaRa, Dalian, China). Q-PCR was performed as described [@B30] using specific primers listed in **Table [S1](#SM0){ref-type="supplementary-material"}**. The relative expression levels were calculated using the comparative threshold cycle (∆∆CT) method.

Whole-mount alcian blue and alizarin red staining
-------------------------------------------------

To detect the morphological changes of tooth and craniofacial structures, 5 dpf zebrafish embryos were collected and fixed in 4% paraformaldehyde overnight. The cartilages and mineralized tissues were stained using alcian blue and alizarin red as previously described [@B26]. Then, the embryos were imaged using a Leica M205 FC Stereomicroscope (Leica Microsystems Nussloch GmbH, Heidelberger, Germany). Phenotypes were quantitatively analyzed by evaluating the length of body, head, ceratohyal and palatoquadrat, the width of head and Meckel´s cartilage, the distance between Meckel\'s cartilage and ceratohyal, and the ceratohyal angle. The amount of calcification was determined according to the intensity of red staining from the attachment point of 4V^1^ tooth in the fifth ceratobranchial arches (cb5) of 5 dpf larvae using the NIH ImageJ software (Wayne Rasband, NIH, USA).

*In situ* hybridization
-----------------------

Embryos were collected and fixed in fresh 4% paraformaldehyde, dehydrated in methanol and stored at -20 °C until use. *In situ* probe primers targeting Sp7 transcription factor (*sp7*) (also known as osterix), α1 chain of collagen type X (*col10a1*), connexin 43 (*cx43*), distal-less homeobox 2b (*dlx2b*), and even-skipped-like1 (*eve1*) were synthesized and listed in **Table [S2](#SM0){ref-type="supplementary-material"}**. All probes were amplified from cDNA derived from 2 dpf embryos and subcloned into pEASY-T3 (TransGen Biotech, Beijing, China). *In situ* probe synthesis was performed using Digoxigenin RNA Labeling Kit (SP6/T7, Roche Diagnostics, Mannheim, Germany). Whole-mount *in situ* hybridization (WISH) was performed using the standard procedure [@B31]. Embryos were mounted into glycerin, and imaged using Leica M205 FC Stereomicroscope (Leica Microsystems Nussloch GmbH, Heidelberger, Germany).

Scanning electron microscope observation
----------------------------------------

Zebrafish larvae at 5 dpf were fixed in 4% paraformaldehyde overnight and stained by alcian blue and alizarin red. After that, the tooth and cb5 were isolated and incubated with 2% sodium hypochlorite for 2 min. The ultrastructure of zebrafish teeth was observed by scanning electron microscope (HITACHI S-4800, Tokyo, Japan) [@B27].

Western blot
------------

A total of 50 embryos from each group were collected at 3dpf. A 15 μg of protein per sample was loaded into 10% SDS-PAGE gel. The following primary antibodies were used: rabbit anti-phospho-SMAD2 (Ser465/467) (138D4) monoclonal antibody (1/500, Cell Signaling, Boston, USA), rabbit anti-SMAD2 (D43B4) monoclonal antibody (1:500, Cell Signaling, Boston, USA), rabbit anti-phospho-SMAD1 (Ser463/465)/SMAD5 (Ser463/465)/SMAD9 (Ser465/ 467) (D5B10) monoclonal antibody (1:1000, Cell Signaling, Boston, USA), rabbit anti-SMAD1/5/9 (ab66737) polyclonal antibody (1:500, Abcam, Cambridge, England), rabbit anti-CTSK polyclonal antibody (1:500, Proteintech, Chicago, USA ), and mouse anti-GAPDH monoclonal antibody (1:1000, Sigma, St. Louis, Missouri, USA). Secondary antibodies included horseradish peroxidase (HRP)-conjugated goat anti-mouse and goat anti-rabbit secondary antibodies (Cowbio, Beijing, China). Chemiluminescence signals were detected by ChemiDoc MP (Bio RAD, California, USA). Signals were quantified with ImageJ (Wayne Rasband, NIH, USA).

LysoSensor staining
-------------------

Live 3 dpf embryos were incubated with 1 μM LysoGreen (KeyGen Biotech, Nanjing, China) in embryo media for 30 min at 28.5 °C in dark. Embryos were then rinsed three times using fresh embryo media, and observed by using fluorescence microscopy (Leica M165 FC, Heidelberger, Germany).

Primary culture of mouse bone marrow stromal cells (BMSCs) and *Clcn7* siRNA transfection
-----------------------------------------------------------------------------------------

Six-week-old male Balb/c mice were scarified by cervical dislocation. BMSCs were flushed from the femur and tibia, and then were cultured with α-MEM (Gibico, Grand Island, NY, USA) medium containing 20% FBS (Hyclone, logan, Utah, USA). The protocol has been described in our previous studies [@B32].

The small interfering RNA (siRNA) duplexes targeting the mouse *Clcn7* gene was designed and synthesized by GenePharma (Shanghai, China) according to GenBank™ (NM_011930.3). The sequences of *Clcn7* siRNA were as follows: sense, 5\'-GAGGAGGAAAGACGAAUCATT-3\'; antisense, 5\'- UGAUUCGUCUUUCCUCCUCTT-3\'. The control siRNA was used as the following: sense, 5\'-UUCUCCGAACGUGUCACGUTT-3\'; antisense, 5\'-ACGUGACACGUUCGGAGAATT-3\'.

The 2nd passage BMSCs that reached up to 80% confluence were transfected with *Clcn7* siRNA or control siRNA using lipofectin 2000 (Invitrogen, Carlsbad, USA). After 48 h, the cells were collected for Q-PCR and western blot analysis. The primers were listed in **Table [S1](#SM0){ref-type="supplementary-material"}**.

Drug Treatments
---------------

SB431542 (Selleck, Houston, USA), an effective inhibitor of the canonical TGF-β pathway, was dissolved at a concentration of 10 µM in DMSO. Control MO or *clcn7* MO was injected into zebrafish embryos at one-cell stage. Then, 10 µM SB431542 was added at 14- to 15-somites stage and equal amount of DMSO was used as control. The culture medium was changed every 48 h and 5 dpf embryos were used for whole-mount alcian blue and alizarin red staining.

Results
=======

Clinical craniofacial and dental characteristics of osteopetrosis patients
--------------------------------------------------------------------------

Among the 80 reviewed osteopetrosis cases, there were 51 autosomal recessive osteopetrosis (ARO) and 29 autosomal dominant osteopetrosis (ADO) patients, respectively. The typical craniofacial features of these osteopetrosis patients included macrocephaly, trapezoidal shape of head, frontal bossing, changes in the shape and proportions of facial skeletons and abnormal lateral and superior orbital walls. X-ray of calvarium showed thickened and three-layer calvarium, or hair-on-end appearance. Absence or poor pneumatization of sinuses, nasal obstruction and hypertelorism were commonly observed in the middle of the face and sinuses. Mandibular malformation was characterized by mandibular hypoplasia, widened and deepened mandible with increased gonial angle and short mandibular body. The abnormalities associated with tooth included malformed roots and crowns, missing teeth, poorly calcified teeth, abnormal pulp spaces, absence of tooth buds, caries, and enamel dysplasia. All of the above changes were more frequently observed in ARO than in ADO (**Table [1](#T1){ref-type="table"}**). Other craniofacial abnormalities included osteomyelitis, necrotic bone and fistulae. The ratios of osteomyelitis in ARO and ADO were 47% and 34%, respectively.

Craniofacial and dental characteristics of osteopetrosis patients with *CLCN7* mutations
----------------------------------------------------------------------------------------

Family A presented an autosomal dominant pattern of inheritance (**Figure [1](#F1){ref-type="fig"}A**). The proband II~1~ was diagnosed with osteopetrosis at the age of four. His major clinical symptoms included multiple fractures, anemia and interventricular septal defect, malocclusion (**Figure [1](#F1){ref-type="fig"}D**), mandibular osteomyelitis, facial bone dysplasia, and increased bone mineral density (**Figure [1](#F1){ref-type="fig"}B-C**). The proband carried c.746C\>T (p. Pro477Leu) mutation in*CLCN7* gene. His brother (II~3~) showed increased bone mineral density of the spine without other obvious symptoms and craniofacial malformations (**Figure [1](#F1){ref-type="fig"}E~1~**, **E~2~**). His mother (I~2~) and daughter (III~1~) carried the same mutation, but showed no obvious clinical symptoms.

The proband (II~1~) in family B was 29 years old. Her radiographs revealed a general increase of bone density in the jaws, clavicle and ribs. Her major symptoms included delayed growth rate, short stature, multiple bone fractures and severe anemia. The main craniofacial features included recurrent osteomyelitis in the facial region, malocclusion, maxillofacial and mandiblular dysplasia, macrocephaly and frontal bossing (**Figure [1](#F1){ref-type="fig"}F-K**). The proband presented compound heterozygous mutations in *CLCN7* gene (c.856C\>T, p. Arg286Trp; c.1430T\>C, p. Leu 477 Pro) and the variant c.1430T\>C in exon 16 was inherited from her mother (**Figure [1](#F1){ref-type="fig"}A**). Her mother reported no obvious clinical symptoms. Detailed information about family C and family D was reported previously [@B6], and the two probands have typical craniofacial and tooth features including osteomyelitis and unerupted teeth with root dysplasia.

To sum up, the craniofacial and dental features in the four pedigrees with *CLCN7* mutations, three cases (II~1~ in family A, family B and family C, respectively) presented typical craniofacial features of osteopetrosis such as macrocephaly, frontal bossing, and changes in shape and proportions of facial skeleton. The cases belonged to intermediate autosomal osteopetrosis (IRO) or severe ADO type II (ADO II), and their craniofacial features matched the general osteopetrosis analysis results. Meanwhile, clinical variations, even in a pedigree with the same *CLCN7* mutation, were observed, which were consistent with the previous report [@B33]. More details of craniofacial and dental features in the four pedigrees were presented in **Table [2](#T2){ref-type="table"}**.

Spatial and temporal expression of *clcn7* in early zebrafish development
-------------------------------------------------------------------------

As shown in **Figure [2](#F2){ref-type="fig"}A**, the maternal mRNA signals of *clcn7* were detected during the cleavage stage of the embryos (4 cell, 8 cell), and then ubiquitously expressed during the blastula period (4 hpf). Expression of *clcn7* was confined to the enveloping layer (EVL) surrounding the embryo during the gastrula and bud stages (7 hpf, 10 hpf). The positive expression location of *clcn7* was present in the head including brain, eye and jaw from 1 dpf to 4 dpf. An intensive expression was also found in the ceratobranchial arches at 4 dpf. The consistent transcript level of *clcn7* was confirmed by Q-PCR (**Figure [2](#F2){ref-type="fig"}B**). This expression pattern suggested that *clcn7* might be involved in the development of brain, eye or craniofacial bone.

ClC-7 deficiency causes zebrafish craniofacial defects
------------------------------------------------------

According to our clinical data analysis, ARO and ADO II cases with *CLCN7* mutations showed specific malformations of craniofacial bones and mandibles. Consistently, knockdown of *clcn7* by morpholino in zebrafish embryos resulted in shorter body, smaller head and craniofacial abnormalities when compared with control, MO-injected embryos (**Figure [3](#F3){ref-type="fig"}A-B**). To evaluate the efficiency of MO, *CLCN7* mRNA containing *clcn7* MO target sequence were co-injected into embryos, and the results showed rescuing of craniofacial phenotypes (**Figure [3](#F3){ref-type="fig"}A-B**). These data indicated that *clcn7* was required for patterning of zebrafish craniofacial skeleton.

There were a series of craniofacial cartilage defects in *clcn7* morphants, including altered ceratohyal (Ch) angle (**Figure [3](#F3){ref-type="fig"}A, C-D**), increased distance from Meckel\'s cartilage (M) to Ch and shorter length of Ch and palatoquadrate (Pq) (**Figure [3](#F3){ref-type="fig"}F**), which may contribute to shorter head. In contrast to control morphants, *clcn7* morphants displayed the defects or even loss of ceratobranchial arches (**Figure [3](#F3){ref-type="fig"}A**), and enlarged or inversed Ch angle (**Figure [3](#F3){ref-type="fig"}A, D**). Interestingly, the position of otolith was also changed in *clcn7* morphants with comparable calcification degree (**Figure [3](#F3){ref-type="fig"}A, E**).

*clcn7* morphants demonstrated hypocalcification of most of the bones with weak red alizarin red staining (**Figure [3](#F3){ref-type="fig"}A**). WISH and Q-PCR analysis confirmed significant decrease in the expression levels of *sp7* and *col10a1* (**Figure [3](#F3){ref-type="fig"}G-H**) in *clcn7* morphants. Thus, these evidences confirmed that *clcn7* was crucial for craniofacial development and mineralization in zebrafish, explaining the craniofacial abnormalities in human osteopetrosis involved *CLCN7* mutations. There was a wide variety of the aforementioned craniofacial abnormalities in *clcn7* MO group, which mimicked the variable phenotypic changes in osteopetrosis cases with *CLCN7* mutations.

Loss of *clcn7* function leads to zebrafish tooth defects
---------------------------------------------------------

According to the aforementioned clinical analysis, osteopetrosis patients with/without *CLCN7* mutations showed a higher rate of defective teeth. Consistent with these findings, we also observed significant changes in tooth shape and number of *clcn7* morphants. Histological staining revealed that teeth 3V^1^, 4V^1^ and 5V^1^ with regular morphology were conspicuously found in the control morphants at 5dpf (**Figure [4](#F4){ref-type="fig"}A**). In contrast, only 70% *clcn7* morphants had 4V^1^ tooth and 30% of them had 3V^1^ and 5V^1^ tooth (**Figure [4](#F4){ref-type="fig"}A, C**). The configuration of teeth was also malformed and exhibited decreased calcium deposition in *clcn7* morphants (**Figure [4](#F4){ref-type="fig"}A-B**). SEM observation demonstrated that the control tooth 4V^1^ presented smooth and coherent surface, whereas rough and porous surface was visible in the teeth of *clcn7* morphants (**Figure [4](#F4){ref-type="fig"}D**).

To better understand the involvement of ClC-7 mechanisms of tooth defects, several markers of tooth development were assessed including *dlx2b*, a tooth epithelium and mesenchymal marker [@B34], *cx43*, expressed in odontoblasts and ameloblasts [@B34], *eve1*, expressed in ameloblasts of 4V^1^ [@B35], and *sp7*, a marker for tooth and osteoblast differentiation [@B36]. WISH analysis showed that all *dlx2b*, *cx43*, *eve1* and *sp7* genes were prominently abolished in *clcn7* morphants (**Figure [5](#F5){ref-type="fig"}A** and**Figure [3](#F3){ref-type="fig"}G**), and Q-PCR confirmed the downregulation of *dlx2b*, *cx43*, *eve1* and *sp7* with*clcn7* deficiency (**Figure [5](#F5){ref-type="fig"}B** and **Figure [3](#F3){ref-type="fig"}H**). These results illustrate that knockdown of *clcn7* affected tooth development and calcification including enameloid changes in zebrafish.

Lysosomal abnormalities and reduced CTSK expression in *clcn7* deficient zebrafish
----------------------------------------------------------------------------------

ClC-7 is localized in late endosomes and lysosomes, and its deficiencies led to defective lysosome in mammals [@B23]. There was a pronounced increase of LysoTracker intensity in the head of *clcn7* morphants, especially in the brain and jaw, whereas no noticeable signals were detected in the control morphants (**Figure [6](#F6){ref-type="fig"}A**). This implied that *clcn7* deficiency also led to impaired lysosomal function in zebrafish.

It has been reported that perturbation of lysosomal function leads to alterations in the activity of cathepsin proteases such as CTSK. Not surprisinggly, we detected a remarkable decrease of CTSK in *clcn7* morphants (**Figure [6](#F6){ref-type="fig"}B**), which was consistent with the previous report regarding the reduced expression of *CTSK* mRNA in ADO II patient [@B37].

As varied craniofacial changes of*clcn7* morphants were found, we wondered whether the *clcn7* expression level showed a dose-dependent effect on the phenotypes of craniofacial bones. *clcn7* morphants were divided into severe and mild groups according to the major changes in Ch angle and severe group had the reversal Ch angle (Ch angle \>180º). The expression level of *clcn7* was lower in the severe group than in the mild group. The *ctsk* mRNA level was parallelly down-regulated in the *clcn7* morphants with severe craniofacial changes (**Figure [6](#F6){ref-type="fig"}C**). These findings manifested new insights into the role of CTSK in *CLCN7*-related osteopetrosis.

ClC-7 deficiency disrupted the balance between BMP signaling and TGF-β signaling
--------------------------------------------------------------------------------

The transcript levels of *bmp2b*, *bmpr1ba, bmpr1bb, bmpr2a*, and *bmpr2b* (**Figure [6](#F6){ref-type="fig"}D**) as well as BMP downstream signaling phosphorylated SMAD1/5/8 (pSMAD1/5/8) showed significant reduction in *clcn7* morphants (**Figure [6](#F6){ref-type="fig"}F**). TGF-β-propagated Smad2/3 signals usually balanced the changes of BMP-regulated Smad1/5/8 signals in matured chondrocytes [@B38]. Unsurprisingly, the levels of phosphorylated SMAD2 (pSMAD2) and *tgfbr2a* were prominently higher in *clcn7* morphants compared to controls (**Figure [6](#F6){ref-type="fig"}E, G**). These data demonstrated that knockdown of *clcn7* led to unbalance between TGF-β and BMP signaling, which, therefore, changed the pattern and development of craniofacial bone and tooth in zebrafish.

ClC-7 deficiency caused similar CTSK/BMP changes in mouse BMSCs
---------------------------------------------------------------

After *Clcn7* siRNA transfection, the expression of *Clcn7* in BMSCs was downregulated. Subsequently, the mRNA expression levels of *Ctsk* were decreased in BMSCs, and so did the expression levels of *Bmp2*, *Bmpr1a, Bmpr1b and Smad1* (**Figure [6](#F6){ref-type="fig"}I**). The protein level of pSMAD1/5/8 was reduced and that of pSMAD2 was increased in *Clcn7* deficiency BMSCs, respectively (**Figure [6](#F6){ref-type="fig"}J, K**).

SB431542 inhibitor of TGF-β pathway rescued the craniofacial defects of *clcn7* morphants
-----------------------------------------------------------------------------------------

Imbalance in TGF-β/BMP signaling contributes to craniofacial phenotypes of *clcn7* morphants, while the disruption of this imbalance might rescue some other phenotypes. As the level of TGF-β- propagated Smad2/3 signals was relatively increased, SB431542, a selective small molecule inhibitor of the activin receptor-like kinase (ALK)-4, ALK-5, and ALK-7, has been shown to selectively block TGF-β1 signaling by preventing phosphorylation of SMAD2 without affecting BMP signaling [@B39]-[@B41]. To avoid perturbations in the early developmental roles of TGF-β family signaling, embryos were treated with 10 μM SB431542 during 14- to 15-somite stages. Compared to the controls (**Figure [7](#F7){ref-type="fig"}A**), most *clcn7* MO embryos exhibited enlarged or inversed Ch angle (**Figure [7](#F7){ref-type="fig"}B**). SB431542-treated *clcn7* morphants exhibited partial restoration of Ch angle (**Figure [7](#F7){ref-type="fig"}D**). Quantitation of changes in phenotypic severity revealed a significant shift in the number of mutants from severe to mild phenotypes. Under DMSO treatment, the *clcn7* deficient embryos with enlarged Ch angle and inversed Ch angle were 16.67% and 52.22%, respectively (**Figure [7](#F7){ref-type="fig"}I**). Under SB431542 treatment, the *clcn7* deficient embryos with enlarged Ch angle and inversed Ch angle were switched to 66.67% and 7.78%, respectively (**Figure [7](#F7){ref-type="fig"}I**). Consistent with these findings, we found significant rescued tooth phenotypes in SB431542-treated*clcn7* morphants (**Figure [7](#F7){ref-type="fig"}E-H**). 98% of SB431542-treated *clcn7* morphants had 4V^1^ tooth compared to 70% of *clcn7* deficient embryos under DMSO treatment (**Figure [7](#F7){ref-type="fig"}J**). Thus, SB431542 treatment prevented the severity of craniofacial bone and tooth defects to some extent.

Discussion
==========

Craniofacial and tooth characteristics have been reported in osteopetrosis since 1965 [@B42] and were summarized during early 1992 [@B43]. Review of the literatures and our own clinical data showed that ARO and severe ADO II osteopetrosis more likely cause craniofacial and tooth changes, which also occurred in osteopetrosis cases with *CLCN7* mutations. The typical craniofacial features in osteopetrosis with *CLCN7* mutations and in *Clcn7* mutant mice [@B11] suggested that ClC-7 might affect the formation pattern of craniofacial structures.

Our zebrafish results demonstrated that reduced *clcn7* signaling led to aberrations in craniofacial chondrogenesis and osteogenesis, including shorter Ch and Pq, defective Ch, abnormal Ch angle, and poorly mineralized bones. The above pharyngeal arch loss or reversal and neurocranial abnormalities mimicked the craniofacial changes in osteopetrosis patients and *clcn7^-/-^* mice [@B44],[@B11], suggesting that the regulation of ClC-7 on the craniofacial development and pattern of craniofacial structures were conservative.

Type X collagen is expressed by hypertrophic chondrocytes during endochondral ossification. As a bone-specific transcription factor [@B45], SP7 is required for the differentiation of mesenchymal stem cells and osteoblasts as well as bone formation [@B46]. Diseases associated with SP7, which include osteogenesis imperfecta and zebrafish *sp7* mutants, cause poor differentiation of teeth [@B47]. Both the intensity of alizarin red staining in craniofacial bones and teeth as well as the expression of *col10a1* and *sp7* were reduced in *clcn7* morphants, indicating that ClC-7 deficiency impaired the calcification of craniofacial bones and teeth. Clinical osteopetrosis reports and our pedigree analysis demonstrated that craniofacial bones, such as mandibles or maxilla, showed hypodysplasia or malformation, and were more liable to osteomyelitis; our study data on zebrafish are consistent with the above clinical manifestation of craniofacial bones.

Pycnodysostosis is another bone genetic disorder with increased radiographic bone density. As reported previously, the characteristics of head and craniofacial bones in pycnodysostosis patient, [@B48] including macrocephaly, frontal bossing, changes in the shape and proportions of facial skeleton, were similar to those of osteopetrosis patients summarized in this report. CTSK is the causative gene of pycnodysostosis [@B49]. *In situ* hybridization showed strong staining of *ctsk* in craniofacial regions, pharyngeal arch and Meckels cartilage of zebrafish [@B50]. ClC-7 locates lysosomes in most cell types [@B10],[@B51]. *clcn7* knockdown in zebrafish showed lysosomal storage, which is consistent with previous studies in *Clcn7/ Ostm1* gene knockout mice [@B10],[@B23],[@B24], and the cells lacking either ClC-7 or OSTM1[@B23],[@B48]. The protease activity of CTSK relies much on intracellular conditions such as lysosomal pH. Therefore, lysosomal storage of *clcn7* knockdown of zebrafish is probably the key for the impairment of the expression and activity of CTSK.

The clinical variations of osteopetrosis with *CLCN7* mutations have been previously reported [@B52],[@B53] and noticed in our patients as well. Here, we also found that the variable phenotypes of craniofacial bones were related to the amount of ClC-7 and CSTK. The connection between ClC-7 and CSTK was the key influential factor for craniofacial bone development and pattern formation (**Figure [6](#F6){ref-type="fig"}C** and **Figure [7](#F7){ref-type="fig"}K**).

The impact of BMPs on zebrafish development has been explored in the past decades [@B54]-[@B56]. BMP signals, such as *bmp2a*, *bmp2b*, and *bmp4*, existed in zebrafish pharyngeal teeth during initiation and morphogenesis stages. BMP signaling is required for cranial development, including lower jaw, ventral arch and palate [@B17],[@B57],[@B58], and tooth formation [@B59],[@B60]. In addition to BMP signaling pathway, TGF-β signaling pathway also contributes to the development of craniofacial bone and tooth as well as several patterning events during early embryonic development, including proper craniofacial development [@B61], neurocranial and pharyngeal arch chondrogenesis [@B62]. Imbalance between TGF-β and BMP signaling causes secondary craniofacial malformations in mucolipidosis II [@B63], which was also found in our *clcn7* morphants. BMSCs were the major cells involved in bone development, and we further confirmed that ClC-7 deficiency also resulted in the imbalance between TGF-β and BMP signaling pathways at the cellular level of BMSCs. Together, ClC-7 deficiency impaired lysosomal condition- dependent CTSK, which may in turn modulate TGF-β/BMP signaling to regulate early craniofacial bone development and pattern formation (**Figure [7](#F7){ref-type="fig"}L**).

Of the 80 osteopetrosis cases, 84% presented tooth abnormalities. Our clinical and mice data also confirmed that ClC-7 deficiency resulted in tooth abnormalities such as tooth dysplasia, impacted teeth, and root dysplasia. We further demonstrated the conservative function of ClC-7 in the regulation of tooth formation. *dlx2b* belongs to distal-less (Dlx) family and plays a role in the development of forebrain, craniofacial and tooth [@B64] as well as split-hand/foot formation [@B65]. The reduced*dlx2b* mRNA level might explain tooth malformation and tooth agenesis in *clcn7* morphants, as well as tooth problems of osteopetrosis with *CLCN7* mutations.

Another striking feature was that enameloid dysplasia and hypocalcification in *clcn7* morphants matched the high ratio of enamel dysplasia in osteopetrosis cases. *eve1* is required for the differentiation of ameloblasts and for the initiation and morphogenesis of the first tooth in zebrafish [@B35]. *cx43* encodes connexin 43 in zebrafish, and reduced levels of *Cx43* resulted in ameloblast dysregulation, enamel hypoplasia, and secondary tissue responses [@B66]. The reduced mRNA levels of *eve1*, *cx43*, and mineralization-related molecule *sp7* might explain the morphological and calcification changes of enamel.

Conclusion
==========

In conclusion, *clcn7* acts as a key factor for the regulation of craniofacial bone and tooth formation by targeting lysosomes, CTSK and downstream TGF-β/BMP signaling pathway. Our study provided new insights into the regulatory mechanisms of *clcn7* in zebrafish craniofacial embryonic bone and tooth development, and put forward a mechanism chain of ClC-7/CTSK/TGF-β/BMP/SMAD to explain the typical craniofacial bone and tooth changes in osteopetrosis or even pycnodysostosis patients. Meanwhile, we found that the inhibitors of TGF-β signaling pathway could rescue the craniofacial bone and tooth phenotypes in *clcn7*-deficient zebrafish. These data suggest a new idea for the future treatment of craniofacial pathologies associated with osteopetrosis as well as pycnodysostosis.
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ADO

:   autosomal dominant osteopetrosis

ADO II

:   autosomal dominant osteopetrosis, type II

ARO

:   autosomal recessive osteopetrosis

BMP

:   bone morphogenetic protein

BMSCs

:   bone marrow stromal cells

ClC-7

:   voltage-gated chloride channel 7

*CLCN7*

:   human ClC-7 gene

*Clcn7*

:   mouse ClC-7 gene

*clcn7*

:   zebrafish ClC-7 gene

*col10a1*

:   α1 chain of collagen type X

*cx43*

:   connexin 43; *dlx2b*: distal-less homeobox 2b

*eve1*

:   even-skipped-like1

IRO

:   intermediate autosomal osteopetrosis

pSMAD1/5/8

:   phosphorylated SMAD1/5/8

pSMAD2

:   phosphorylated SMAD2

Q-PCR

:   quantitative real time polymerase chain reaction

*sp7*

:   Sp7 transcription factor

TGF-β

:   transforming growth factor β

WISH

:   whole-mount *in situ* hybridization.
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![**Pedigree and clinical examinations. (A)** Pedigree maps. Family A presented an autosomal dominant pattern of inheritance with c.746C\>T mutation in *CLCN7* gene. Black and grey represented severe phenotypes and no complaint of symptoms, respectively. The proband (II~1~) in family B carried compound heterozygous mutations in *CLCN7* gene (c.856C\>T; c.1430T\>C) and the variant c.1430T\>C in exon 16 was inherited from her mother. **(B-D)** Radiographic images of II~1~ in family A. Increased bone density in chest **(B)** and long bones **(C)**. Malformation of craniofacial bones and tooth abnormalities in orthopantomography of II~1~ **(D)**. **(E1-E2)** Radiographic images of II~3~ in family A. Sandwich vertebral changes. **(F-K)** Clinical images of individual II~1~ in family B. **(F-H)** Typical craniofacial deformities including macrocephaly, frontal bossing, and changes in shape and proportions of facial skeleton. Osteomyelitis and fistulae in the left facial bones. **(I-J)** Intraoral photography and orthopantomography showed malocclusion and tooth malformation. **(K)** Hypoplasia of facial skeletons from CT images.](thnov09p1387g001){#F1}

![**Spatial and temporal expression patterns of *clcn7* during zebrafish early development. (A)** WISH results. *clcn7* was detected during cleavage stage (4 cell, 8 cell) in whole cells at blastula stage (4 hpf), especially in the enveloping layer at gastrula and bud stages (7 hpf, 10 hpf) in the head of embryos from 1dpf to 4dpf. Strong signaling appeared in pharyngeal arches from the ventral portion (3 dpf, 4 dpf). **(B)** Q-PCR results of*clcn7*. The red arrow indicates pharyngeal arches. dpf: days post-fertilization. hpf: hours post-fertilization. Error bars represent standard deviation. Each experiment was repeated at least three times. Scale bars: 100 μm.](thnov09p1387g002){#F2}

![**Craniofacial bone and cartilage abnormalities in *clcn7* morphants. (A)** Craniofacial phenotype comparison between control and *clcn7* morphants. Cranial cartilages (blue) and mineralized bones (red) were stained with alcian blue and alizarin red in control and *clcn7* morphants at 5 dpf, respectively. **(A-C)** Compared to WT and Control embryos, *clcn7* morphants showed more malformed craniofacial skeletons, and *clcn7* mRNA rescued the abnormalities in craniofacial region. **(D, E)** Abnormal ceratohyal (Ch) angle and altered location of otolith in *clcn7* morphants. **(F)** Quantitative analysis of a series of changes of phenotypic indexes. *clcn7* morphants showed obvious changes in the pattern of craniofacial structure. **(G)** WISH analysis showed the abolished expression of *sp7* and *col10a1* in cranial skeleton, most notably in the parasphenoid (Ps) and opercle (Op) bones in *clcn7* morphants at 3 dpf. **(H)** Q-PCR analysis confirmed the reduced level of *sp7* and*col10a1*. For A-E, WT n=300, Control MO n=320, *clcn7* MO n=300, *clcn7* MO + mRNA n=182. For H: Control MO n=50, *clcn7* MO n=50. The red arrow indicates abnormal Ch angle, and the white arrow points to abnormal otolith. Ch: ceratohyal. M: Meckel\'s. Op: opercle. Pq: palatoquadrate. Ps: parasphenoid. WT: wide type. Error bar represents the SD. The experiment was repeated at least thrice with the same conditions. \* *p*\<0.05, \*\* *p*\<0.01, \*\*\**p*\<0.001. Scale bars: 100 μm.](thnov09p1387g003){#F3}

![**Defective tooth phenotypes in *clcn7*-deficient zebrafish. (A)** Alcian blue and alizarin red staining results of 5^th^ ceratobranchial arch and teeth in control and *clcn7* morphants at 5dpf. The malformed teeth were fewer with weak red staining *clcn7* morphants. **(B)** Quantitative comparison of the extent of calcification among WT embryos, control and *clcn7* morphants. **(C)** Comparison of embryonic tooth number. WT and control embryos had 3V^1^, 4V^1^ and 5V^1^ teeth, while *clcn7* morphants showed 3V^1^, 4V^1^ and 5V^1^ fewer teeth. **(D)** Ultrastructure of tooth 4V^1^ in control and *clcn7* morphants. *clcn7* morphants had malformed tooth and enameloid dysplasia. Red arrows point to the pits on the enameloid surface. For A, B, D: WT n=50, Control MO n=50, *clcn7* MO n=50. The white square in the first image of figure A is the region for measuring calcified content in panel B. Error bar represents the SD. The experiment was repeated thrice with the same conditions. The data in image C was one of the representative experimental results. WT n=300, Control MO n=320, *clcn7* MO n=300. \*\* *p*\<0.01, \*\*\**p*\<0.001. Scale bars: 100 μm.](thnov09p1387g004){#F4}

![**Molecular changes in the teeth of *clcn7*-deficient zebrafish. (A-B)** WISH and Q-PCR analysis results. The fair expression of *dlx2b*, *cx43*, and *eve1* in the teeth of *clcn7* morphants at 3 dpf were diminished compared to that in control morphants. The data in image B was one of the representative experimental results. Error bar represents the SD. Control MO n=50, *clcn7* MO n=50. The experiment was repeated thrice with the same conditions. \*\*\**p*\<0.001. Scale bars: 100 μm.](thnov09p1387g005){#F5}

![***clcn7* deficiency led to lysosomal storage, reduced Cathepsin K expression and imbalanced TGF-β/BMP signaling pathway. (A)** LysoTracker staining revealed lysosomal storage in the brain and jaw in*clcn7* morphants at 3dpf compared to control morphants. The insets showed higher magnification of the white boxed areas in*clcn7* morphants. **(B)** Western blot and quantification analysis showed that CTSK protein was markedly decreased in *clcn7* morphants at 3dpf. **(C)** Comparison of *clcn7* and *ctsk* level using Q-PCR detection. The mRNA level of *clcn7* and *ctsk* showed a dose-dependent parallel downregulation with severe craniofacial changes. **(D, E)** Q-PCR analysis results. Transcript levels of *bmp2b* and *bmpr1ba, bmpr1bb, bmpr2a*, *bmpr2b* were decreased, the levels of *tgfb1a*, *tgfb1b* were declined and that of *tgfbr2a* was increased in *clcn7* morphants compared to controls at 3dpf. **(F, G and H)** Western blots results. The protein levels of pSMAD1/5/8 proteins were significantly reduced, while pSMAD2 levels were increased compared to control. **(I)** Q-PCR results of BMSCs. Compared to controls, the transcript levels of *Bmp2* and *Bmpr1a, Bmpr1b, Smad1* and *Ctsk* were decreased in *Clcn7* siRNA group. **(J, K)** Western blot analysis showed that *Clcn7* siRNA increased the protein levels of pSMAD2, while pSMAD1/5/8 levels were reduced compared to controls. For B-H: Control MO n=50, *clcn7* MO n=50, *clcn7* MO mild n=50, *clcn7* MO severe n=50. All data represent mean ±SD. The experiment was repeated at least thrice with the same conditions. ns: not significant difference. \* *p*\<0.05, \*\* *p*\<0.01, \*\*\**p*\<0.001. Scale bars: 100 μm.](thnov09p1387g006){#F6}

![**Inhibition of TGF-β signaling partially rescues craniofacial abnormalities in*clcn7* deficient zebrafish. (A-D)** Ventral views of 5dpf zebrafish with alcian blue and alizarin red staining. Control zebrafish treated with DMSO **(A)** or 10 μM SB431542 **(C)** showed no obvious changes of Ch angle. **(B)** *clcn7* knockdown zebrafish treated with DMSO showed abnormal Ch angle, and 10 μM SB431542 partially rescued Ch angle, showing significant differences **(D, I)**. **(E-H)** Comparison of embryonic tooth number among controls and *clcn7* morphants treated with DMSO or 10 μM SB431542.**(J)** *clcn7* morphants treated with 10 μM SB431542 showed the higher eruption rate of 4V^1^ tooth. **(K)** Schematic correlation between the amount of ClC-7 and craniofacial/tooth phenotypes in humans and zebrafish. ARO showed more and severe craniofacial/tooth phenotypes than ADO. The more severe the craniofacial phenotypes in *clcn7* morphants, the lower level of *clcn7* and *ctsk*, which further results in the imbalance between TGF-β and BMP signals, affecting the craniofacial and tooth development. **(L)** Schematic representation of ClC-7- and CTSK-mediated TGF-β/BMP pathway in zebrafish. *clcn7* deficiency led to impaired lysosomal function and reduced CTSK expression. TGF-β-like Smad2 signals are elevated and BMP-like Smad1/5/8 signals are reduced in *clcn7* knockdown zebrafish, which may contribute to the imbalance in TGF-β/BMP signaling during craniofacial and tooth development. The experiment was repeated thrice with the same conditions. The data in image J was one of the representative experimental results. For A-J: Control MO DMSO n=210, Control MO SB431542 n=198, *clcn7* MO DMSO n=158, *clcn7* MO SB431542 n=134. Scale bars: 100 μm.](thnov09p1387g007){#F7}

###### 

Summary of craniofacial and tooth abnormalities in osteopetrosis patients from literature review.

  -------------------------------------------------------------------------------------------
  Abnormalities                                     ARO\          ADO\          Total\
                                                    (cases, %)    (cases, %)    (cases, %)
  ------------------------------------------------- ------------- ------------- -------------
  **Tooth**                                         45/51 (88%)   22/29 (76%)   67/80 (84%)

  **Mandible**                                      33/51 (65%)   9/29 (31%)    42/80 (53%)

  **Middle of face and sinuses**                    28/51 (55%)   8/29 (28%)    36/80 (45%)

  **Osteomyelitis**                                 24/51 (47%)   10/29 (34%)   34/80 (43%)

  **Fistulae**                                      13/51 (26%)   6/29 (21%)    19/80 (24%)

  **Calvarium**                                     32/51 (63%)   9/29 (31%)    41/80 (51%)

  **Frontal bossing**                               28/51 (55%)   6/29 (21%)    34/80 (43%)

  **Shape and proportion of the facial skeleton**   38/51 (75%)   13/29 (45%)   51/80 (64%)

  **Hearing**                                       18/51 (35%)   5/29 (17%)    23/80 (29%)
  -------------------------------------------------------------------------------------------

ARO: autosomal recessive osteopetrosis, ADO: autosomal dominant osteopetrosis.

###### 

Information of individuals with *CLCN7* mutations.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family   No.                     DNA\                              Predicted Protein Change (NP_001278.1)   Genotype         Subtype        Radiographic changes   Anemia     Craniofacial Phenotypes   Dental Phenotypes   Age at diagnosis
                                   Nucleotide Change (NM_001287.5)                                                                                                                                                            
  -------- ----------------------- --------------------------------- ---------------------------------------- ---------------- -------------- ---------------------- ---------- ------------------------- ------------------- ------------------
  **A**    I~2~                    c.746C\>T                         p.Pro249\>Leu                            heterozygous     asymptomatic   mild                   absent     absent                    absent              N/A

  II~1~    c.746C\>T               p.Pro249\>Leu                     heterozygous                             ADO II           serve          moderate               moderate   moderate                  4 years old         

  II~3~    c.746C\>T               p.Pro249\>Leu                     heterozygous                             ADO II           serve          absent                 mild       mild                      7 years old         

  III~1~   c.746C\>T               p.Pro249\>Leu                     heterozygous                             asymptomatic\*   mild           absent                 absent     absent                    N/A                 

  **B**    I~2~                    c.1430T\>C                        p.Leu477Pro                              heterozygous     asymptomatic   N/A                    absent     absent                    N/A                 N/A

  II~1~    c.856C\>T; c.1430T\>C   p.Arg286Trp; p.Leu477Pro          compound heterozygous                    IRO              severe         severe                 severe     severe                    3-4 years old       

  **C**    I~2~                    c.1409C\>T                        p.Pro470Leu                              heterozygous     asymptomatic   N/A                    absent     absent                    N/A                 N/A

  II~1~    c.1409C\>T              p.Pro470Leu                       homozygous                               IRO              severe         severe                 severe     severe                    6-7 years old       

  **D**    II~1~                   c.856C\>T                         p.Arg286Trp                              heterozygous     ADO II         moderate               absent     moderate                  moderate            6 years old
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N/A: not available; \* polydactyly; IRO: intermediate autosomal osteopetrosis; ADO II: autosomal dominant osteopetrosis, type II.
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